Spain and Boston — A Structured Connection Between Two Complementary Ecosystems
Spain is the first implementation of Dreavent's Bio Asset Engineering Platform
Spain has a strong and growing scientific base, with world-class research institutions, a deep pool of scientific talent, and an increasing number of biotech companies with differentiated programs and validated biology.
Boston is where the BD and R&D decision-makers of every major pharmaceutical company, the deepest concentration of specialized life sciences capital, and the talent that has navigated the FDA pathway repeatedly and successfully all coexist.
Connecting these two ecosystems in a structured and permanent way is the goal. In this industry, internationalization is not geographical expansion: it is integrating the asset into the world's most efficient biotech development infrastructure to minimize risk and maximize valuation.
The Translational Unit — The Linking Team
A specialized team operating simultaneously in Spain and in Boston. On one side, it analyzes the science of Spanish biotech companies. On the other, it maintains ongoing dialogue with global pharmaceutical companies to understand their strategic pipeline needs. A company is only selected when a pharmaceutical partner has confirmed interest.
The $200M Dreavent Engine Fund
The financial vehicle that makes the entire connection possible, deploying capital across the Spain Track ($100M) and the U.S. Clinical Track ($100M), governed by a single principle: we only invest where a pharmaceutical company is already on the cap table or has expressed interest in the asset.
The Boston Development Platform
Once selected, each asset enters the Boston Development Platform, developed in partnership with Syneos Health, the world's third largest clinical development organization, with 22,000 professionals across 100+ countries, providing clinical expertise, regulatory knowledge, and site access the FDA development pathway requires.
The Institutional Bridge
The connection between Spain and Boston was structured and activated through the Richi Foundation. Ricardo García, Founder of the Richi Foundation and Co-founder & CEO of Oncoheroes Biosciences, played a key role in building the institutional interface between both ecosystems.
The Alliance
The Spain–Boston initiative is backed at the highest institutional level by both governments — a recognition that this model addresses a structural need on both sides. For Spain, it builds the mechanism to convert its scientific base into globally competitive biotech assets. For Massachusetts, it demonstrates that Boston can attract international private capital at scale through structured bilateral connections with complementary scientific ecosystems.
Institutional Support
Spanish Government — COFIDES / ICEX / FIEX
Commonwealth of Massachusetts
City of Boston
M&T Bank